Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report)'s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $11.21, but opened at $10.06. Ono Pharmaceutical shares last traded at $10.06, with a volume of 274 shares trading hands.
Ono Pharmaceutical Stock Performance
The stock has a market capitalization of $5.21 billion, a price-to-earnings ratio of 15.86 and a beta of 0.49. The company has a quick ratio of 2.56, a current ratio of 3.07 and a debt-to-equity ratio of 0.13. The stock's 50-day simple moving average is $10.35 and its 200 day simple moving average is $10.58.
About Ono Pharmaceutical
(
Get Free Report)
Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.
Further Reading
Before you consider Ono Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ono Pharmaceutical wasn't on the list.
While Ono Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
